Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 4 of 4 publications.

Layton JB, Forns J, McQuay LJ, Danysh HE, Dempsey C, Anthony MS, Turner ME. Plain language summary of mortality rates of patients with Parkinson's disease psychosis who were treated either with pimavanserin or with different second-generation (atypical) antipsychotics. Futur Neurol. 2025 Feb 28;20(1). doi: 10.1080/14796708.2025.2463315

Herring WL, Gould IG, Wittrup-Jensen V, Ertle J, Kuti E, Wolowacz S. Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes. J Comp Eff Res. 2022 Dec 1;11(18):1349-63. doi: 10.2217/cer-2021-0194

Joshi K, Muser E, Xu Y, Schwab P, Datar M, Suehs B. Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population. J Comp Eff Res. 2018 Aug;7(8):723-35. doi: 10.2217/cer-2018-0003

Meyers J, Gajria K, Candrilli SD, Fridman M, Sikirica V. The impact of adjunctive guanfacine extended release on stimulant adherence in children/adolescents with attention-deficit/hyperactivity disorder. J Comp Eff Res. 2017 Mar;6(2):109-25. doi: 10.2217/cer-2016-0039